Applied Molecular Transport Inc. (AMTI) News
Filter AMTI News Items
AMTI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest AMTI News From Around the Web
Below are the latest news stories about APPLIED MOLECULAR TRANSPORT INC that investors may wish to consider to help them evaluate AMTI as an investment opportunity.
Applied Molecular Transport Insider Ups Holding By 239% During YearLooking at Applied Molecular Transport Inc.'s ( NASDAQ:AMTI ) insider transactions over the last year, we can see that... |
Applied Molecular Transport Reports Third Quarter 2023 Financial ResultsCompany Entered into Definitive Merger Agreement with Cyclo Therapeutics Cash and Cash Equivalents of $18.1 million, as of September 30, 2023 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023. Recent Business Highlights and Anticipated Milestones Entered into a definitive merger agreement with Cyclo Therapeutics Combined |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayPre-market stock movers are a hot topic this morning and we're checking on the biggest ones investors will want to watch on Friday! |
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger AgreementGAINESVILLE, Fla. & SOUTH SAN FRANCISCO, Calif., September 21, 2023--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and Applied Molecular Transport Inc. (Nasdaq: AMTI) ("AMT"), a biopharmaceutical company, announced today that the companies have entered into a definitive agreement (the Merger Agreement) pursuant |
Applied Molecular Transport Reports Second Quarter 2023 Financial ResultsCurrently Pursuing Strategic Alternatives, with MTS Health Partners, L.P. Advising the Company Cash and Cash Equivalents of $22.5 million, as of June 30, 2023 SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2023. Financial Results for the Second Quarter Ended June 30, 2023 Research and development (R&D) expenses. Total R&D expen |
Positive Signs As Multiple Insiders Buy Applied Molecular Transport Stock \When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase... |
Applied Molecular Transport Reports First Quarter 2023 Financial ResultsSOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2023. Recent Business Highlights Engaged MTS Health Partners, L.P. as advisors in a process to explore strategic alternatives for the companyAppointed Shawn Cross to serve as chief executive officer and board chairTahir Mahmood, Ph.D., co-founder and former CEO remains a member of t |
Applied Molecular Transport Announces Corporate Leadership Change and Process to Explore Strategic AlternativesSOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the company’s board of directors approved a workforce reduction of approximately 57% of its employee base and the engagement of MTS Health Partners, L.P. as advisors in a process to explore strategic alternatives for the company. As part of the restructuring, Tahir Mahmood, Ph.D., will leave his post as chief execu |
What Makes Applied Molecular Transport Inc. (AMTI) a New Buy StockApplied Molecular Transport Inc. (AMTI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Applied Molecular Transport Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateExploring strategic partnership options to advance AMT-101 for chronic pouchitis, an orphan indication with no FDA-approved products Evaluating next steps for the company's second clinical asset, AMT-126 SOUTH SAN FRANCISCO, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2022. “We we |